142 related articles for article (PubMed ID: 33091667)
1. Identification of a potent and selective phosphatidylinositol 3-kinase δ inhibitor for the treatment of non-Hodgkin's lymphoma.
Zuo WQ; Hu R; Wang WL; Zhu YX; Xu Y; Yu LT; Liu ZH; Wang NY
Bioorg Chem; 2020 Dec; 105():104344. PubMed ID: 33091667
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and structure-activity relationship study of piperazinone-containing thieno[3,2-d]pyrimidine derivatives as new PI3Kδ inhibitors.
Wang NY; Zuo WQ; Hu R; Wang WL; Zhu YX; Xu Y; Yu LT; Liu ZH
Bioorg Med Chem Lett; 2020 Oct; 30(20):127479. PubMed ID: 32784091
[TBL] [Abstract][Full Text] [Related]
3. INCB040093 Is a Novel PI3K
Shin N; Li YL; Mei S; Wang KH; Hall L; Katiyar K; Wang Q; Yang G; Rumberger B; Leffet L; He X; Rupar M; Bowman K; Favata M; Li J; Liu M; Li Y; Covington M; Koblish H; Soloviev M; Shuey D; Burn T; Diamond S; Fridman J; Combs A; Yao W; Yeleswaram S; Hollis G; Vaddi K; Huber R; Newton R; Scherle P
J Pharmacol Exp Ther; 2018 Jan; 364(1):120-130. PubMed ID: 29127109
[TBL] [Abstract][Full Text] [Related]
4. Dual Inhibition of Bruton's Tyrosine Kinase and Phosphoinositide-3-Kinase p110
Alfaro J; Pérez de Arce F; Belmar S; Fuentealba G; Avila P; Ureta G; Flores C; Acuña C; Delgado L; Gaete D; Pujala B; Barde A; Nayak AK; Upendra TVR; Patel D; Chauhan S; Sharma VK; Kanno S; Almirez RG; Hung DT; Chakravarty S; Rai R; Bernales S; Quinn KP; Pham SM; McCullagh E
J Pharmacol Exp Ther; 2017 May; 361(2):312-321. PubMed ID: 28298527
[TBL] [Abstract][Full Text] [Related]
5. Design of Novel Phosphatidylinositol 3-Kinase Inhibitors for Non-Hodgkin's Lymphoma: Molecular Docking, Molecular Dynamics, and Density Functional Theory Studies on Gold Nanoparticles.
Ali AM; Makki AA; Ibraheem W; Abdelrahman M; Osman W; Sherif AE; Ashour A; Ibrahim SRM; Ghazawi KF; Samman WA; Alzain AA
Molecules; 2023 Mar; 28(5):. PubMed ID: 36903539
[TBL] [Abstract][Full Text] [Related]
6. Structurally novel PI3Kδ/γ dual inhibitors characterized by a seven-membered spirocyclic spacer: The SARs investigation and PK evaluation.
Tao Q; Chen Y; Liang X; Hu Y; Li J; Fang F; Wang H; Meng C; Liang J; Ma X; Gui S
Eur J Med Chem; 2020 Apr; 191():112143. PubMed ID: 32078865
[TBL] [Abstract][Full Text] [Related]
7. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142
[TBL] [Abstract][Full Text] [Related]
8. Design and Optimization of Thienopyrimidine Derivatives as Potent and Selective PI3Kδ Inhibitors for the Treatment of B-Cell Malignancies.
Zhang J; Jiang H; Lin S; Wu D; Tian H; Jiang L; Cui Y; Jin J; Chen X; Xu H
J Med Chem; 2022 Jun; 65(11):8011-8028. PubMed ID: 35609190
[TBL] [Abstract][Full Text] [Related]
9. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
Lampson BL; Brown JR
Expert Opin Investig Drugs; 2017 Nov; 26(11):1267-1279. PubMed ID: 28945111
[TBL] [Abstract][Full Text] [Related]
10. Idelalisib for the treatment of indolent non-Hodgkin's lymphoma.
Lopez JP; Jimeno A
Drugs Today (Barc); 2014 Feb; 50(2):113-20. PubMed ID: 24619588
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of novel benzothiadiazine derivatives as potent PI3Kδ-selective inhibitors for treating B-cell-mediated malignancies.
Ma X; Wei J; Wang C; Gu D; Hu Y; Sheng R
Eur J Med Chem; 2019 May; 170():112-125. PubMed ID: 30878826
[TBL] [Abstract][Full Text] [Related]
12. Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3Kδ/γ Inhibitor RP6530.
Locatelli SL; Careddu G; Serio S; Consonni FM; Maeda A; Viswanadha S; Vakkalanka S; Castagna L; Santoro A; Allavena P; Sica A; Carlo-Stella C
Clin Cancer Res; 2019 Feb; 25(3):1098-1112. PubMed ID: 30352904
[TBL] [Abstract][Full Text] [Related]
13. TYM-3-98, a novel selective inhibitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B-cell lymphomas.
Lou SY; Zheng FL; Tang YM; Zheng YN; Lu J; An H; Zhang EJ; Cui SL; Zhao HJ
Life Sci; 2024 Jun; 347():122662. PubMed ID: 38670450
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of benzofuro[3,2-b]pyridin-2(1H)-one derivatives as anti-leukemia agents by inhibiting Btk and PI3Kδ.
Liu L; Shi B; Li X; Wang X; Lu X; Cai X; Huang A; Luo G; You Q; Xiang H
Bioorg Med Chem; 2018 Aug; 26(15):4537-4543. PubMed ID: 30077608
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Evaluation of Novel 2H-Benzo[e]-[1,2,4]thiadiazine 1,1-Dioxide Derivatives as PI3Kδ Inhibitors.
Gong YP; Tang LQ; Liu TS; Liu ZP
Molecules; 2019 Nov; 24(23):. PubMed ID: 31775363
[TBL] [Abstract][Full Text] [Related]
16. Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase
Shin N; Stubbs M; Koblish H; Yue EW; Soloviev M; Douty B; Wang KH; Wang Q; Gao M; Feldman P; Yang G; Hall L; Hansbury M; O'Connor S; Leffet L; Collins R; Katiyar K; He X; Waeltz P; Collier P; Lu J; Li YL; Li Y; Liu PCC; Burn T; Covington M; Diamond S; Shuey D; Roberts A; Yeleswaram S; Hollis G; Metcalf B; Yao W; Huber R; Combs A; Newton R; Scherle P
J Pharmacol Exp Ther; 2020 Jul; 374(1):211-222. PubMed ID: 32345620
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of novel selective PI3Kδ inhibitors containing pyridopyrimidine scaffold.
Ma M; Feng Y; Zhang SQ; Duan W; Gao L; Yuan B; Xin M
Future Med Chem; 2023 Aug; 15(16):1491-1509. PubMed ID: 37565336
[No Abstract] [Full Text] [Related]
18. Discovery of 2-(2-aminopyrimidin-5-yl)-4-morpholino-N-(pyridin-3-yl)quinazolin-7-amines as novel PI3K/mTOR inhibitors and anticancer agents.
Peng W; Tu ZC; Long ZJ; Liu Q; Lu G
Eur J Med Chem; 2016 Jan; 108():644-654. PubMed ID: 26731167
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel quinazolinone derivatives as high potent and selective PI3Kδ and PI3Kδ/γ inhibitors.
Ma CC; Zhang CM; Tang LQ; Liu ZP
Eur J Med Chem; 2018 May; 151():9-17. PubMed ID: 29601991
[TBL] [Abstract][Full Text] [Related]
20. Novel 6-aryl substituted 4-pyrrolidineaminoquinazoline derivatives as potent phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
Xin M; Duan W; Feng Y; Hei YY; Zhang H; Shen Y; Zhao HY; Mao S; Zhang SQ
Bioorg Med Chem; 2018 May; 26(8):2028-2040. PubMed ID: 29534936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
